John Hanna, M.D., Ph.D.
Instructor in Pathology, Harvard Medical School & Brigham & Women's Hospital

The goal of her research is to develop novel biomedical interventions to prevent and treat HIV. In particular, she is interested in the design and evaluation of HIV vaccines and monoclonal antibodies that can be effective in the face of tremendous HIV sequence diversity.

Randall King, M.D., Ph.D.
Harry C. McKenzie Professor of Cell Biology, Harvard Medical School

The goal of our research program is to understand how cell division is regulated, both in normal cells and in cancer cells. We are especially interested in the role of ubiquitin-dependent proteolysis in regulating progression through mitosis. To approach these problems, we integrate biochemical, cell biological, and chemical approaches.

Deborah Hung, M.D., Ph.D.
Associate Professor of Microbiology and Immunobiology, Harvard Medical School and Massachusetts General Hospital

The goal of research in the Hung Lab is to understand in vivo mechanisms of bacterial pathogenesis by studying pathogen-host interactions. By merging the fields of chemical genetics and bacterial genetics/genomics, we hope to provide insight into possible new paradigms for addressing infectious diseases.

Dan Barouch, M.D., Ph.D.
Professor of Medicine, Harvard Medical School

His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. His laboratory has explored a series of novel vaccine technologies, including adjuvanted DNA vaccines, poxvirus vectors, and alternative serotype adenovirus vectors in both preclinical and clinical studies.

Kathryn Stephenson, M.D., M.P.H.
Assistant Professor of Medicine, Harvard Medical School

The goal of her research is to develop novel biomedical interventions to prevent and treat HIV. In particular, she is interested in the design and evaluation of HIV vaccines and monoclonal antibodies that can be effective in the face of tremendous HIV sequence diversity.
Mary Mullen M.D., Ph.D.
Assistant Professor of Pediatrics, Harvard Medical School

Dr. Mullen is an Associate in Cardiology and Associate Director, Pediatric Pulmonary Hypertension Program at Boston Children’s Hospital. She regularly publishes research on pediatric pulmonary hypertension.

Harold Burstein M.D., Ph.D.
Associate Professor of Medicine, Harvard Medical School

In the Breast Oncology Center, our clinical trials help define new treatment options for women with early-stage and advanced breast cancer. We have conducted several NCI-supported phase II trials of angiogenesis inhibitors in advanced breast cancer. These studies analyzed clinical outcomes for treatment with standard or low-dose “metronomic” chemotherapy (also thought to have anti-angiogenic potential) in combination with bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody. The primary endpoints of these studies are to characterize the response rate and safety profile of treatments.